Abel Hall LLC’s Trevi Therapeutics TRVI Stock Holding History

Abel Hall LLC’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,191	Closed	-$128K	–	971
2025 Q4	$128K	Buy	+10,191	New	+$118K	0.03%	593

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Abel Hall LLC's TRVI Position: Q1 2026 in Review

Abel Hall LLC sold out of Trevi Therapeutics (TRVI) in Q1 2026, closing a stake of 10,191 shares — an estimated $128K sold.

Abel Hall LLC first reported a position in TRVI in Q4 2025 and held it in 1 quarter. The position peaked at $128K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

Abel Hall LLC reported no remaining Trevi Therapeutics position as of Q1 2026 after selling out during the quarter.
Abel Hall LLC sold 10,191 Trevi Therapeutics shares in Q1 2026, an estimated $128K.
Abel Hall LLC first reported a position in Trevi Therapeutics in Q4 2025 and held it in 1 quarter.
Abel Hall LLC's Trevi Therapeutics position peaked at $128K in Q4 2025.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.